Merck and Kaluga pharmcluster signed a partnership agreement

| By | Drug Development, Kaluga Pharmcluster, R&D
0
1214

The collaboration with Merck, a science and technology company, assumes active cooperation for the development life science technologies in the Kaluga region. The parties defined the priority areas for their collaboration, such as creating joint infrastructure projects, laboratories for personnel training and competence centers; creating partner projects with the participants of Kaluga pharmaceutical cluster based on advanced technology solutions from Merck; implementing R&D projects.

“We are already actively working with Merck on a number of scientific and educational projects and, for that reason, the signing of agreement on strategic cooperation is a logical step in the development of partnership and a landmark event for the region. By 2020, Kaluga pharmaceutical cluster expects to become one of top three leaders in Life Science. I am confident that this partnership will open for us new infrastructure and educational opportunities offered by one of the leading science and technology companies in this area,” said Irina Novikova, the Executive Director of Kaluga Pharmaceutical Cluster, a non-profit partnership.

“We view the development and support of science and technology partnerships in Russia as part of our mission. I am confident that close collaboration and synergy of efforts with such a strong regional player as the Kaluga pharmaceutical cluster will open to us new opportunities for steady technology transfer and will provide Russian experts with access to advanced developments of our company,” said Juergen Koenig, President and General Director, Merck Russia & CIS.